The comparison of PRCA with and without T-LGLL
| . | Without PRCA, . | With PRCA, . | P . |
|---|---|---|---|
| T-LGLL, n = 18 . | T-LGLL, n = 11 . | ||
| Lymphocytes, median (range), ×109/L | 1.32 (0.31-2.27) | 4.12 (0.95-7.50) | 6.2 × 10−5* |
| CD8+ T cells, median (range), ×109/L | 0.34 (0.22-0.80) | 3.33 (0.87-5.51) | 3.1 × 10−6* |
| Reticulocytes, median (range), ×109/L | 7.1 (0-27.8) | 12.8 (4.8-23.4) | .12 |
| LD, median (range), IU/L | 197 (137-351) | 194 (159-350) | .8 |
| Erythroblasts in BM, median (range), % | 0.8 (0-5.2) | 1.4 (0.2-4.4) | .47 |
| TCRγ monoclonality | 3/18 | 11/11 | 2.3 × 10−6* |
| Skewed TCRβ repertoire | 3/10 | 6/7 | .049* |
| Therapy | |||
| CsA | 11 | 10 | .26 |
| Steroid | 6 | 3 | 1 |
| CY | 1 | 5 | .019* |
| Multiple | 3 | 5 | .2 |
| STAT3 | |||
| Mutated | 6 | 9 | .021* |
| Mutated in SH2 domain | 5 | 7 | .12 |
| VAF in PBMNC, median (range), % | 5.1 (2.0-48.9) | 1.9 (0.57-5.6) | .083 |
| AsPCR+ | 2 | 6 | .033* |
| . | Without PRCA, . | With PRCA, . | P . |
|---|---|---|---|
| T-LGLL, n = 18 . | T-LGLL, n = 11 . | ||
| Lymphocytes, median (range), ×109/L | 1.32 (0.31-2.27) | 4.12 (0.95-7.50) | 6.2 × 10−5* |
| CD8+ T cells, median (range), ×109/L | 0.34 (0.22-0.80) | 3.33 (0.87-5.51) | 3.1 × 10−6* |
| Reticulocytes, median (range), ×109/L | 7.1 (0-27.8) | 12.8 (4.8-23.4) | .12 |
| LD, median (range), IU/L | 197 (137-351) | 194 (159-350) | .8 |
| Erythroblasts in BM, median (range), % | 0.8 (0-5.2) | 1.4 (0.2-4.4) | .47 |
| TCRγ monoclonality | 3/18 | 11/11 | 2.3 × 10−6* |
| Skewed TCRβ repertoire | 3/10 | 6/7 | .049* |
| Therapy | |||
| CsA | 11 | 10 | .26 |
| Steroid | 6 | 3 | 1 |
| CY | 1 | 5 | .019* |
| Multiple | 3 | 5 | .2 |
| STAT3 | |||
| Mutated | 6 | 9 | .021* |
| Mutated in SH2 domain | 5 | 7 | .12 |
| VAF in PBMNC, median (range), % | 5.1 (2.0-48.9) | 1.9 (0.57-5.6) | .083 |
| AsPCR+ | 2 | 6 | .033* |
CsA, cyclosporine A; CY, cyclophosphamide; LD, lactate dehydrogenase; TCR, T-cell receptor; VAF, variant allele frequency.
Significantly different.